Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1621 1628
This examiner grants 54% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18250494 | FORMULATIONS OF AZOBENZENE PHOTOREACTIVE COMPOUNDS | Non-Final OA | The Regents of the University of California |
| 18009035 | TLR7 INHIBITOR IN COMBINATION WITH PREDNISOLONE OR HYDROXYCHLOROQUINE FOR TREATING CUTANEOUS LUPUS ERYTHEMATOSUS | Final Rejection | BRISTOL-MYERS SQUIBB COMPANY |
| 19182228 | RESTORING FUNCTION OF SPECIFIC MUTATIONS AFFECTING THE ACTIN DYNAMIC BY ADMINISTRATION OF SAPROPTERIN | Final Rejection | QRGenetics Ltd. |
| 18423444 | REGULATION OF MUTANT TERT BY BRAF V600E/MAP KINASE PATHWAY THROUGH FOS/GABP IN HUMAN CANCER | Final Rejection | THE JOHNS HOPKINS UNIVERSITY |
| 18271102 | METHODS FOR PREVENTING OR TREATING CONDITIONS RELATED TO T CELL MEDIATED INTESTINAL DISORDERS | Non-Final OA | The Regents of the University of Michigan |
| 18260115 | TOCOTRIENOL COMPOSITIONS AND METHODS TO TREAT NON-ALCOHOLIC STEATOHEPATITIS | Final Rejection | THE TRUSTEES OF INDIANA UNIVERSITY |
| 18825447 | NEW TREATMENT | Final Rejection | Verona Pharma Limited |
| 18417864 | ENSIFENTRINE (RPL554) FOR TREATING MODERATE COPD | Final Rejection | Verona Pharma Limited |
| 18751933 | IMMUNE MEMORY INDUCTION BY PLATINUM BASED COMPOUNDS | Non-Final OA | AKAMARA THERAPEUTICS, INC. |
| 18428488 | METHODS OF TREATING SEIZURE DISORDERS AND PRADER-WILLI SYNDROME | Final Rejection | Ovid Therapeutics Inc. |
| 17999240 | ANTI-FIBROTIC COMPOSITION AND RELATED METHODS | Final Rejection | Fred Hutchinson Cancer Center |
| 18376679 | Cannabinoid Composition and Uses Thereof | Non-Final OA | Brains Bioecutical Corp |
| 17926214 | COMPOSITIONS AND METHODS OF MODULATING SHORT-CHAIN DEHYDROGENASE ACTIVITY | Non-Final OA | Board of Regents of the University of Texas System |
| 18467687 | APPLICATION OF ION CHANNEL BLOCKER IN TREATMENT AND/OR PREVENTION OF HEPATIC FIBROSIS | Final Rejection | Affiliated Hospital of Zunyi Medical University |
| 18246415 | LINE-1 INHIBITORS TO TREAT DISEASE | Non-Final OA | Transposon Therapeutics, Inc. |
| 17926992 | PHARMACEUTICAL FORMULATIONS AND THEIR PREPARATIONS FOR TREATMENT OF CANCER | Non-Final OA | Cellix Bio Private Limited |
| 18261563 | INHIBITORS OF DYRK AND PIM | Non-Final OA | VICHEM CHEMIE RESEARCH, LTD. |
| 18272219 | COMPOSITION INCLUDING DECURSINOL AS ACTIVE INGREDIENT FOR PREVENTING OR TREATING SMOOTH MUSCLE CELL PROLIFERATIVE DISEASES | Non-Final OA | KYUNGSUNG UNIVERSITY INDUSTRY COOPERATION FOUNDATION |
| 18009347 | OPHTHALMIC COMPOSITIONS COMPRISING A COMBINATION OF FLUOROQUINOLONE ANTIBACTERIAL AGENT AND AN ANTI-INFLAMMATORY AGENT | Final Rejection | SENTISS PHARMA PRIVATE LIMITED |
| 18270017 | A COMPOSITION FOR USE IN THE TREATMENT OF RECTAL AND/OR INTESTINAL INFLAMMATION | Non-Final OA | CANNAMORE BIOTECHS LTD. |
| 18270001 | METHODS OF METABOLIZING METOPIMAZINE AND ITS SALTS | Non-Final OA | Neurogastrx, Inc. |
| 18323488 | Methods and Treatment for Complex Lymphatic Malformations | Non-Final OA | Avalo Therapeutics, Inc. |
| 17187880 | Early Stage Detection for Alzheimers and other Autoimmune Diseases | Final Rejection | VOC HEALTH, INC. |
| 18026834 | COMPOUNDS FOR TREATMENT OF HEART FAILURE | Non-Final OA | Sulfateq B.V. |
| 18044294 | USE OF TRIAZOLE ANALOGUES FOR INHIBITION OF A TRIPARTITE VOR PROTEIN COMPLEX IN MULTICELLULAR ORGANISMS | Non-Final OA | Gaspare SPEDALE |
| 18022611 | NOVEL COMPOSITIONS AND METHODS FOR THE TREATMENT OF LUNG FIBROSIS | Non-Final OA | LAURENT PHARMACEUTICALS INC. |
| 18004665 | LENALIDOMIDE PRODRUGS, POLYMERIC CONJUGATES, AND FORMULATIONS THEREOF, AND THEIR USES FOR THE TREATMENT OF MULTIPLE MYELOMA | Non-Final OA | DYNAMIC BIOLOGICS INC. |
| 18014367 | TRPV4 INHIBITOR AS A THERAPEUTIC AGENT FOR OCULAR DISEASES | Non-Final OA | RaQualia Pharma Inc. |
| 17994877 | PEDICULICIDAL COMPOSITION | Non-Final OA | Pelthos Therapeutics Inc. |
| 17798477 | FIBROTIC DISEASE MECHANISM AND THERAPEUTIC DRUG THEREFOR | Non-Final OA | GUANGZHOU WOMEN AND CHILDREN'S MEDICAL CENTER |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy